Lurasidone meets schizophrenia endpoint

Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) said once-daily 80 mg lurasidone met the primary endpoint of a significant reduction from baseline in PANSS total score over six weeks vs. placebo (23.4 vs. 17 points) in the Phase III PEARL 1 trial to treat schizophrenia. Once-daily 40 and 120 mg lurasidone missed the endpoint in the double-blind, international trial in 500 patients. Data were presented at the American Psychiatric Association meeting in San Francisco. ...